Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer.
Seneca Therapeutics has raised $3.9M in total funding. The most recent round was Series B. The last funding was announced in August 2025.
Seneca Therapeutics's investors include Keiretsu Capital, Broad Street Angels, Mid Atlantic Bio Angels, K4 Forum Mumbai Network.
Seneca Therapeutics is headquartered in Blue Bell, United States.
Seneca is a biotechnology company that focuses on developing novel oncolytic immunotherapeutics for the treatment of cancer.
Seneca Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Seneca Therapeutics — Funding & Investors." VCBacked, August 28, 2025, https://www.vcbacked.co/company/seneca-therapeutics. Accessed October 30, 2026.
VCBacked. (2025). Seneca Therapeutics — Funding & Investors. Retrieved October 30, 2026, from https://www.vcbacked.co/company/seneca-therapeutics
{{cite web |title=Seneca Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/seneca-therapeutics |website=VCBacked |access-date=October 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated